Redmile Group, LLC Bei Gene, Ltd. Transaction History

Redmile Group, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$120.61 - $148.29 $4.81 Million - $5.92 Million	-39,900 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$113.99 - $146.86 $56,995 - $73,430	-500 Reduced 1.24%	39,900 $4.95 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $10,701 - $17,515	100 Added 0.25%	40,400 $5.67 Million
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $45,750 - $65,031	300 Added 0.75%	40,300 $6.2 Million
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $3.9 Million - $7.09 Million	40,000 New	40,000 $0

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.1B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.